Literature DB >> 20012173

Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Xiaoyu Yan1, Donald E Mager, Wojciech Krzyzanski.   

Abstract

Target-mediated drug disposition (TMDD) models have been applied to describe the pharmacokinetics of drugs whose distribution and/or clearance are affected by its target due to high binding affinity and limited capacity. The Michaelis-Menten (M-M) model has also been frequently used to describe the pharmacokinetics of such drugs. The purpose of this study is to investigate conditions for equivalence between M-M and TMDD pharmacokinetic models and provide guidelines for selection between these two approaches. Theoretical derivations were used to determine conditions under which M-M and TMDD pharmacokinetic models are equivalent. Computer simulations and model fitting were conducted to demonstrate these conditions. Typical M-M and TMDD profiles were simulated based on literature data for an anti-CD4 monoclonal antibody (TRX1) and phenytoin administered intravenously. Both models were fitted to data and goodness of fit criteria were evaluated for model selection. A case study of recombinant human erythropoietin was conducted to qualify results. A rapid binding TMDD model is equivalent to the M-M model if total target density R ( tot ) is constant, and R ( tot ) K ( D ) /(K ( D ) + C) ( 2 ) << 1 where K ( D ) represents the dissociation constant and C is the free drug concentration. Under these conditions, M-M parameters are defined as: V ( max ) = k ( int ) R ( tot ) V ( c ) and K ( m ) = K ( D ) where k ( int ) represents an internalization rate constant, and V ( c ) is the volume of the central compartment. R ( tot ) is constant if and only if k ( int ) = k ( deg,) where k ( deg ) is a degradation rate constant. If the TMDD model predictions are not sensitive to k ( int ) or k ( deg ) parameters, the condition of R ( tot ) K ( D ) /(K ( D ) + C) ( 2 ) << 1 alone can preserve the equivalence between rapid binding TMDD and M-M models. The model selection process for drugs that exhibit TMDD should involve a full mechanistic model as well as reduced models. The best model should adequately describe the data and have a minimal set of parameters estimated with acceptable precision.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012173      PMCID: PMC3157300          DOI: 10.1007/s10928-009-9142-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  26 in total

1.  Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.

Authors:  Anson K Abraham; Wojciech Krzyzanski; Donald E Mager
Journal:  AAPS J       Date:  2007-06-08       Impact factor: 4.009

2.  Approximations of the target-mediated drug disposition model and identifiability of model parameters.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Tarundeep Kakkar; Peiming Ma
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-13       Impact factor: 2.745

3.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

4.  Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  Donald E Mager; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

5.  Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.

Authors:  O E Della Paschoa; J W Mandema; R A Voskuyl; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

6.  Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

Authors:  Chee M Ng; Amita Joshi; Russell L Dedrick; Marvin R Garovoy; Robert J Bauer
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

7.  Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Authors:  Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-10       Impact factor: 2.745

8.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Mary C Wacholtz; Neil Minton; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

9.  Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia.

Authors:  N H Al-Huniti; J A Widness; R L Schmidt; P Veng-Pedersen
Journal:  J Pharmacol Exp Ther       Date:  2004-02-26       Impact factor: 4.030

10.  Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.410

View more
  42 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.

Authors:  Xiaoyu Yan; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-04       Impact factor: 2.745

3.  Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.

Authors:  Peiming Ma
Journal:  Pharm Res       Date:  2011-12-01       Impact factor: 4.200

4.  Target-mediated drug disposition model for drugs that bind to more than one target.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-29       Impact factor: 2.745

5.  Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.

Authors:  Anshu Marathe; Wojciech Krzyzanski; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-05-12       Impact factor: 2.745

6.  Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Authors:  A Dubois; S Gsteiger; S Balser; E Pigeolet; J L Steimer; G Pillai; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

7.  A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.

Authors:  Hoai-Thu Thai; Christine Veyrat-Follet; Nicole Vivier; Catherine Dubruc; Gerard Sanderink; France Mentré; Emmanuelle Comets
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

Review 8.  Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Authors:  S Sadekar; I Figueroa; M Tabrizi
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

9.  Target-mediated drug disposition model and its approximations for antibody-drug conjugates.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-12-11       Impact factor: 2.745

10.  Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Authors:  Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-10       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.